



Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation

A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance

William A. Zoghbi, MD, FASE (Chair), David Adams, RCS, RDCS, FASE, Robert O. Bonow, MD, Maurice Enriquez-Sarano, MD, Elyse Foster, MD, FASE, Paul A. Grayburn, MD, FASE, Rebecca T. Hahn, MD, FASE, Yuchi Han, MD, MMSc,* Judy Hung, MD, FASE, Roberto M. Lang, MD, FASE, Stephen H. Little, MD, FASE, Dipan J. Shah, MD, MMSc,* Stanton Shernan, MD, FASE, Paaladinesh Thavendiranathan, MD, MSc, FASE,* James D. Thomas, MD, FASE, and Neil J. Weissman, MD, FASE, *Houston and Dallas, Texas; Durham, North Carolina; Chicago, Illinois; Rochester, Minnesota; San Francisco, California; New York, New York; Philadelphia, Pennsylvania; Boston, Massachusetts; Toronto, Ontario, Canada; and Washington, DC*

TABLE OF CONTENTS

I. Introduction	305		
II. Evaluation of Valvular Regurgitation: General Considerations	305		
A. Identifying the Mechanism of Regurgitation	305		
B. Evaluating Valvular Regurgitation with Echocardiography	305		
1. General Principles	305		
a. Comprehensive imaging	306		
b. Integrative interpretation	306		
c. Individualization	306		
d. Precise language	306		
2. Echocardiographic Imaging	306		
a. Valve structure and severity of regurgitation	306		
b. Impact of regurgitation on cardiac remodeling	307		
3. Color Doppler Imaging	307		
a. Jet characteristics and jet area	308		
b. Vena contracta	309		
c. Flow convergence	309		
4. Pulsed Doppler	310		
a. Forward flow	310		
b. Flow reversal	310		
5. Continuous Wave Doppler	310		
a. Spectral density	310		
b. Timing of regurgitation	310		
c. Time course of the regurgitant velocity	310		
6. Quantitative Approaches to Valvular Regurgitation	311		
a. Quantitative pulsed Doppler method	311		
b. Quantitative volumetric method	312		
c. Flow convergence method (proximal isovelocity surface area [PISA] method)	312		

From Houston Methodist Hospital, Houston, Texas (W.A.Z., S.H.L., D.J.S.); Duke University Medical Center, Durham, North Carolina (D.A.); Northwestern University, Chicago, Illinois (R.O.B., J.D.T.); Mayo Clinic, Rochester, Minnesota (M.E.-S.); University of California, San Francisco, California (E.F.); Baylor University Medical Center, Dallas, Texas (P.A.G.); Columbia University Medical Center, New York, New York, (R.T.H.); Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (Y.H.); Massachusetts General Hospital, Boston, Massachusetts (J.H.); University of Chicago, Chicago, Illinois (R.M.L.); Brigham and Women's Hospital, Boston, Massachusetts (S.S.); Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada (P.T.); and MedStar Health Research Institute, Washington, DC (N.J.W.).

The following authors reported no actual or potential conflicts of interest in relation to this document: David Adams, RCS, RDCS, FASE; Robert O. Bonow, MD; Judy Hung, MD, FASE; Stephen H. Little, MD, FASE; Paaladinesh Thavendiranathan, MD, MSc; and Neil J. Weissman, MD, FASE. The following authors reported relationships with one or more commercial interests: Maurice Enriquez-Sarano, MD, received research support from Edwards LLC; Elyse Foster, MD, FASE, received grant support from Abbott Vascular Structural Heart and consulted for Gilead; Paul A. Grayburn, MD, FASE, consulted for Abbott Vascular, Neochord, and Tendyne and received research support from Abbott Vascular, Tendyne, Valtech, Edwards, Medtronic, Neochord, and Boston Scientific; Rebecca T. Hahn, MD, FASE, is a speaker for Philips Healthcare, St. Jude's Medical, and Boston Scientific; Yuchi Han, MD, MMSc, received research support from Gilead and GE; Roberto M.

Lang, MD, FASE, is on the advisory board of and received grant support from Philips Medical Systems; Dipan Shah, MD, MMSc, received research grant support from Abbott Vascular and Guerbet; Stanton Shernan, MD, FASE, is an educator for Philips Healthcare, Inc.; James D. Thomas, MD, FASE, received honoraria from Edwards and GE, and honoraria, research grant, and consultation fee from Abbott; and William A. Zoghbi, MD, FASE, has a licensing agreement with GE Healthcare and is on the advisory board for Abbott Vascular.

Reprint requests: American Society of Echocardiography, 2100 Gateway Centre Boulevard, Suite 310, Morrisville, NC 27560 (E-mail: ase@asecho.org).

Attention ASE Members:

The ASE has gone green! Visit www.aseuniversity.org to earn free continuing medical education credit through an online activity related to this article. Certificates are available for immediate access upon successful completion of the activity. Nonmembers will need to join the ASE to access this great member benefit!

* Society for Cardiovascular Magnetic Resonance Representative.

0894-7317/\$36.00

Copyright 2017 by the American Society of Echocardiography.

<http://dx.doi.org/10.1016/j.echo.2017.01.007>

Abbreviations

2D = Two-dimensional
3D = Three-dimensional
ACC/AHA = American College of Cardiology/American Heart Association
ARO = Anatomic regurgitant orifice
AR = Aortic regurgitation
ASE = American Society of Echocardiography
CMR = Cardiovascular magnetic resonance
CSA = Cross-sectional area
CWD = Continuous wave Doppler
EROA = Effective regurgitant orifice area
LA = Left atrium, atrial
LV = Left ventricle, ventricular
LVEF = Left ventricular ejection fraction
LVOT = Left ventricular outflow tract
MR = Mitral regurgitation
MV = Mitral valve
MVP = Mitral valve prolapse
PA = Pulmonary artery
PISA = Proximal isovelocity surface area
PR = Pulmonary regurgitation
PRF = Pulse repetition frequency
PV = Pulmonary valve
RF = Regurgitant fraction
RV = Right ventricle, ventricular
RVol = Regurgitant volume
RVOT = Right ventricular outflow tract
SSFP = Steady-state free precession
SV = Stroke volume
TEE = Transesophageal echocardiography
TR = Tricuspid regurgitation
TTE = Transthoracic echocardiography
TV = Tricuspid valve
Va = Aliasing velocity
VC = Vena contracta
VCA = Vena contracta area
VCW = Vena contracta width
VTI = Velocity time integral

- C. Evaluating Valvular Regurgitation with Cardiac Magnetic Resonance 314
 - 1. Cardiac Morphology, Function, and Valvular Anatomy 314
 - a. Ventricular volumes 314

- b. Correct placement of the basal ventricular short-axis slice is critical 314
 - c. Planimetry of LV epicardial contour 315
 - d. Left atrial volume 315
 - 2. Assessing Severity of Regurgitation with CMR 315
 - a. Phase-contrast CMR 315
 - b. Quantitative methods 315
 - c. Technical considerations 317
 - d. Thresholds for regurgitation severity 317
 - 3. Strengths and Limitations of CMR 317
 - 4. When Is CMR Indicated? 317
 - D. Grading the Severity of Valvular Regurgitation 318
- III. Mitral Regurgitation 318
 - A. Anatomy of the Mitral Valve and General Imaging Considerations 318
 - B. Identifying the Mechanism of MR: Primary and Secondary MR 319
 - 1. Primary MR 319
 - 2. Secondary MR 320
 - 3. Mixed Etiology 321
 - C. Hemodynamic Considerations in Assessing MR Severity 323
 - 1. Acute MR 323
 - 2. Dynamic Nature of MR 323
 - a. Temporal variation of MR during systole 323
 - b. Effect of loading conditions 323
 - c. Systolic anterior MV motion 324
 - 3. Pacing and Dysrhythmias 324
 - D. Doppler Methods of Evaluating MR Severity 324
 - 1. Color Flow Doppler 324
 - a. Regurgitant jet area 324
 - b. Vena contracta (width and area) 328
 - c. Flow convergence (PISA) 328
 - 2. Continuous Wave Doppler 330
 - 3. Pulsed Doppler 330
 - 4. Pulmonary Vein Flow 330
 - E. Assessment of LV and LA Volumes 330
 - F. Role of Exercise Testing 330
 - G. Role of TEE in Assessing Mechanism and Severity of MR 330
 - H. Role of CMR in the Assessment of MR 331
 - 1. Mechanism of MR 331
 - 2. Methods of MR Quantitation 331
 - 3. LV and LA Volumes and Function 331
 - 4. When Is CMR Indicated? 331
 - I. Concordance between Echocardiography and CMR 331
 - J. Integrative Approach to Assessment of MR 332
 - 1. Considerations in Primary MR 334
 - 2. Considerations in Secondary MR 334
- IV. Aortic Regurgitation 334
 - A. Anatomy of the Aortic Valve and Etiology of Aortic Regurgitation 334
 - B. Classification and Mechanisms of AR 335
 - C. Assessment of AR Severity 336
 - 1. Echocardiographic Imaging 336
 - 2. Doppler Methods 336
 - a. Color flow Doppler 336
 - b. Pulsed wave Doppler 336
 - c. Continuous wave Doppler 336
 - D. Role of TEE 340
 - E. Role of CMR in the Assessment of AR 340
 - 1. Mechanism 340
 - 2. Quantifying AR with CMR 340
 - 3. LV Remodeling 342
 - 4. Aortopathy 342
 - 5. When Is CMR Indicated? 342
 - F. Integrative Approach to Assessment of AR 343
- V. Tricuspid Regurgitation 345
 - A. Anatomy of the Tricuspid Valve 345

Download English Version:

<https://daneshyari.com/en/article/5609168>

Download Persian Version:

<https://daneshyari.com/article/5609168>

[Daneshyari.com](https://daneshyari.com)